$2.10
-0.48 (-18.60%)
Open$2.40
Previous Close$2.58
Day High$2.45
Day Low$1.69
52W High$3.90
52W Low$1.17
Volume—
Avg Volume1.48M
Market Cap130.93M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,257.1% upside
Current
$2.10
$2.10
Target
$28.50
$28.50
$17.57
$28.50 avg
$41.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 421.2K | 11.04M | 11.56M |
| Net Income | -12,407,759 | -536,425 | -578,623 |
| Profit Margin | -2,928.8% | -4.9% | -5.0% |
| EBITDA | -13,717,044 | -810,707 | -735,622 |
| Free Cash Flow | — | -370,627 | -351,629 |
| Rev Growth | — | +9.7% | -0.5% |
| Debt/Equity | — | 0.96 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |